3-[4-[(2,5-dimethylphenoxy)methyl]-2-({[(1R)-1-(3,5-dimethylphenyl)-3-methylbutyl]amino}carbonyl)phenyl]propanoic acid | 499150-05-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[4-[(2,5-dimethylphenoxy)methyl]-2-({[(1R)-1-(3,5-dimethylphenyl)-3-methylbutyl]amino}carbonyl)phenyl]propanoic acid
• 英文别名: 3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoic acid；3-[4-[(2,5-Dimethylphenoxy)methyl]-2-({[(1R)-1-(3,5-dimethylphenyl)-3-methylbutyl]amino}carbonyl)phenyl]-propanoic acid；3-[4-[(2,5-dimethylphenoxy)methyl]-2-[[(1R)-1-(3,5-dimethylphenyl)-3-methylbutyl]carbamoyl]phenyl]propanoic acid
• CAS: 499150-05-9
• 化学式: C₃₂H₃₉NO₄
• 分子量: 501.666
• InChiKey: CZGCGANYIFZAMH-GDLZYMKVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  37
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-(2-(((1R)-3-methyl-1-(3,5-dimethylphenyl)butyl)carbamoyl)-4-(2,5-dimethylphenoxymethyl)phenyl)propanoic acid methyl ester 在 sodium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 12.0h， 生成 3-[4-[(2,5-dimethylphenoxy)methyl]-2-({[(1R)-1-(3,5-dimethylphenyl)-3-methylbutyl]amino}carbonyl)phenyl]propanoic acid
  参考文献：
  名称：

  3-（2-氨基羰基苯基）丙酸类似物作为有效的和选择性的EP3受体拮抗剂。第3部分：旋光类似物的合成，代谢稳定性和生物学评估

  摘要：

  合成了一系列在羧酰胺侧链上具有（1 R）-1-（3,5-二甲基苯基）-3-甲基丁胺部分的3-（2-氨基羰基苯基）丙酸类似物，并评估了它们对EP1的结合亲和力-4受体及其对EP3受体的拮抗活性。基于人肝微粒体代谢物结构的合理药物设计使我们发现了另一系列类似物。进一步评价了几种化合物在口服给药后在大鼠中的体内功效以及药代动力学特征，包括在肝微粒体中的体外稳定性。

  DOI：

  10.1016/j.bmc.2010.03.028

文献信息

• THERAPEUTIC AGENT FOR PSYCHONEUROTIC DISEASE
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1787657A1

  公开（公告）日：2007-05-23

  The present invention relates to a preventive and/or therapeutic agent for psychoneurotic diseases, comprising an EP3 antagonist represented by the general formula (I): (wherein the meanings of characters are defined in the description). This compound has an antagonistic potency against EP3 and exhibits efficacy through unusual action mechanism as a preventive and/or therapeutic agent for psychoneurotic disorder, psychosomatic disorder, anxiety disorder, depression and disorder caused by stress.

  本发明涉及一种预防和/或治疗心神经疾病的药剂，包括一种由一般公式(I)表示的EP3拮抗剂：（其中字符的含义在描述中定义）。该化合物具有对EP3的拮抗作用，通过不寻常的作用机制作为一种预防和/或治疗心神经紊乱、心身疾病、焦虑症、抑郁症以及由压力引起的疾病的药剂展现出疗效。
• CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT
  申请人：Tani Kousuke

  公开号：US20090318703A1

  公开（公告）日：2009-12-24

  A carboxylic acid derivative of formula (I): wherein R 1 is —COOH, —COOR 6 , etc.; A is a single bond, alkylene, etc.; R 2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R 3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE 2 receptor, especially subtypes EP 3 and/or EP 4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.

  化学式为（I）的羧酸衍生物：其中R1为—COOH，—COOR6等；A为单键，烷基等；R2为烷基，烷氧基等；B为碳环或杂环；Q为烷基烯-Cyc2等；D为连接链；R3为烷基，碳环或杂环，或其无毒盐。化合物（I）与PGE2受体结合，特别是亚型EP3和/或EP4，并显示拮抗活性，对于预防和/或治疗由疼痛、瘙痒、荨麻疹、过敏、尿频、尿液障碍、阿尔茨海默病、癌症、痛经、子宫内膜异位症等引起的疾病有用。
• Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
  申请人：Tani Kousuke

  公开号：US20060258728A1

  公开（公告）日：2006-11-16

  A carboxylic acid derivative of formula (I): wherein R 1 is —COOH, —COOR 6 , etc.; A is a single bond, alkylene, etc.; R 2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R 3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE 2 receptor, especially subtypes EP 3 and/or EP 4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.

  化学式为（I）的羧酸衍生物：其中R1为—COOH，—COOR6等；A为单键，烷基等；R2为烷基，烷氧基等；B为碳环或杂环；Q为烷基烯-Cyc2等；D为连接链；R3为烷基，碳环或杂环，或其无毒盐。化合物（I）与PGE2受体结合，特别是亚型EP3和/或EP4，并显示拮抗活性，可用于预防和/或治疗因疼痛、瘙痒、荨麻疹、过敏、尿频、尿障碍、阿尔茨海默病、癌症、痛经、子宫内膜异位症等引起的疾病。
• Therapeutic agent for psychoneurotic disease
  申请人：Narita Masami

  公开号：US20090286862A1

  公开（公告）日：2009-11-19

  The present invention relates to a preventive and/or therapeutic agent for psychoneurotic diseases, comprising an EP 3 antagonist represented by the general formula (I): (wherein the meanings of characters are defined in the description). This compound has an antagonistic potency against EP 3 and exhibits efficacy through unusual action mechanism as a preventive and/or therapeutic agent for psychoneurotic disorder, psychosomatic disorder, anxiety disorder, depression and disorder caused by stress.

  本发明涉及一种预防和/或治疗精神神经疾病的药剂，其包括一种由通式（I）表示的EP3拮抗剂：（其中字符的含义在描述中定义）。该化合物具有对EP3的拮抗效力，并通过不寻常的作用机制表现出作为预防和/或治疗精神神经障碍、心身障碍、焦虑症、抑郁症和由压力引起的障碍的药剂的功效。
• CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1431267A1

  公开（公告）日：2004-06-23

  A carboxylic acid derivative of formula (I): wherein R1 is -COOH, -COOR6, etc.; A is a single bond, alkylene, etc.; R2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE2 receptor, especially subtypes EP3 and/or EP4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.

  式(I)的羧酸衍生物： 其中 R1 为-COOH、-COOR6 等；A 为单键、亚烷基等；R2 为烷基、烷氧基等；B 为碳环或杂环；Q 为烷基烯-Cyc2 等；D 为连接链；R3 为烷基、碳环或杂环，或其无毒盐。式（I）化合物能与 PGE2 受体，特别是 EP3 和/或 EP4 亚型结合并显示出拮抗活性，可用于预防和/或治疗诱发疼痛、瘙痒、荨麻疹、过敏、尿频、排尿障碍、老年痴呆症、癌症、痛经、子宫内膜异位症等疾病。